Sotera Health (NASDAQ:SHC) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• Sotera Health reported a quarterly earnings per share (EPS) of $0.20, exceeding analyst estimates by $0.03, with revenue reaching $294.34 million compared to expectations of $275.81 million.
• The company's net margin was 2.24% and its return on equity stood at 41.08%, with a year-over-year revenue growth of 6.4%.
• Sotera Health has updated its FY 2025 guidance to an EPS range of 0.750-0.820, and currently has a market capitalization of approximately $3.96 billion.

Sotera Health (NASDAQ:SHC - Get Free Report) posted its earnings results on Friday. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.03, Briefing.com reports. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%. The firm had revenue of $294.34 million for the quarter, compared to analyst estimates of $275.81 million. During the same quarter in the prior year, the company earned $0.19 EPS. Sotera Health's revenue was up 6.4% on a year-over-year basis. Sotera Health updated its FY 2025 guidance to 0.750-0.820 EPS.

Sotera Health Trading Up 3.2%

Shares of SHC stock traded up $0.48 on Wednesday, reaching $15.34. 177,247 shares of the stock were exchanged, compared to its average volume of 1,214,005. The stock has a market cap of $4.36 billion, a P/E ratio of 191.46 and a beta of 1.81. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 4.49. The firm has a 50 day moving average of $11.72 and a two-hundred day moving average of $12.04. Sotera Health has a 1-year low of $9.53 and a 1-year high of $17.08.

Institutional Trading of Sotera Health

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning increased its holdings in shares of Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company's stock worth $224,000 after buying an additional 2,673 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company's stock worth $293,000 after buying an additional 14,018 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Sotera Health by 14.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company's stock worth $3,999,000 after buying an additional 43,471 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in shares of Sotera Health by 11.1% during the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company's stock worth $332,000 after buying an additional 2,845 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on SHC. Barclays reissued an "overweight" rating on shares of Sotera Health in a research note on Friday. Piper Sandler reduced their price target on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Wall Street Zen raised Sotera Health from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Finally, The Goldman Sachs Group raised Sotera Health from a "neutral" rating to a "buy" rating and increased their price target for the stock from $14.00 to $17.00 in a research note on Monday, May 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $16.00.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.